Nuvectis Pharma Inc. Company Profile
NASDAQ: NVCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 3:52 PM ET
Nuvectis Pharma at a glance
Nuvectis Pharma Inc. (NASDAQ: NVCT) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Fort Lee, NJ. Nuvectis Pharma is led by Mr. Ron Bentsur M.B.A. and employs about 16 people. The company's shares have traded publicly since 2022.
At a market capitalization of $653.3 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001875558, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Nuvectis Pharma do?
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Business description based on the company's public filings.
Company information
- Legal name
- Nuvectis Pharma Inc.
- Ticker
- NASDAQ: NVCT
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Ron Bentsur M.B.A.
- Employees
- 16
- Headquarters
- 1 Bridge Plaza, Fort Lee, NJ, United States
- Phone
- 201 614 3150
- Website
- nuvectis.com
- IPO year
- 2022
- Market cap
- $653.26M
- SEC CIK
- 0001875558
- Latest annual report
- 10-K · Feb 11, 2026
Companies similar to Nuvectis Pharma
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZVRAZevra Therapeutics Inc. | 10.98 | -0.90% | $652.03M | vs NVCT |
| FTHFaeth Therapeutics Inc. | 25.34 | +1.69% | $654.80M | vs NVCT |
| IRWDIronwood Pharmaceuticals Inc. Class A | 3.88 | +3.33% | $640.30M | vs NVCT |
| ABUSArbutus Biopharma Corporation | 4.17 | -2.79% | $639.16M | vs NVCT |
| PHARPharming Group N.V. ADS | 9.53 | -1.30% | $674.16M | vs NVCT |
| SGMTSagimet Biosciences Inc. Series A | 8.88 | 0.00% | $629.67M | vs NVCT |
| WVEWave Life Sciences Inc. | 3.45 | -2.54% | $679.82M | vs NVCT |
| OLMAOlema Pharmaceuticals Inc. | 7.77 | -2.14% | $679.86M | vs NVCT |